Faculty Opinions recommendation of Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses.

2010 ◽  
Author(s):  
Glenn Waller
Keyword(s):  
Systematic Review ◽  
Anorexia Nervosa ◽  
Bone Health ◽  
Premenopausal Women ◽  
Meta Analyses

Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: A systematic review and meta-analyses

2009 ◽  
pp. NA-NA ◽  
Author(s):  
Leslie A. Sim ◽  
Lauren McGovern ◽  
Mohamed B. Elamin ◽  
Brian A. Swiglo ◽  
Patricia J. Erwin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anorexia Nervosa ◽  
Bone Health ◽  
Premenopausal Women ◽  
Meta Analyses

scholarly journals Incidence of Anorexia Nervosa in Women: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 17 (11) ◽  
pp. 3824
Author(s):  
Leticia Martínez-González ◽  
Tania Fernández-Villa ◽  
Antonio José Molina ◽  
Miguel Delgado-Rodríguez ◽  
Vicente Martín
Keyword(s):  
Systematic Review ◽  
Anorexia Nervosa ◽  
Young Women ◽  
Hospital Admissions ◽  
Linear Trend ◽  
Meta Analysis ◽  
Healthcare Services ◽  
Online Databases ◽  
Newcastle Ottawa Scale ◽  
Meta Analyses

Background: Anorexia nervosa (AN) among the general population is a rare but often fatal illness. Objective: To summarize the incidence of AN using a systematic review and meta-analysis. Methods: Four online databases (PubMed, Scopus, WoS and Embase) were consulted. The review was conducted according to with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was limited to women. The methodological quality of the studies was assessed by the Newcastle–Ottawa Scale (NOS). Results: A total of 31 articles were included in the study. The incidence rate of AN ranged from 0.5 to 318.0 cases per 100,000 women–years. The incidence in studies based on outpatient healthcare services (OHS) was higher than those based on hospital admissions (HA) (8.8 95% CI: 7.83–9.80 vs. 5.0 95% CI: 4.87–5.05). In young women, the incidence in OHS was higher than HA (63.7, 95% CI 61.21–66.12 vs. 8.1 95% CI 7.60–8.53). The linear trend in the incidence of AN was increasing in all ages of women and young women, both in studies with hospital admission records, and in those based on outpatient healthcare services. Conclusion: The incidence of AN depends on the methodology, the type of population and the diagnostic criteria used.

scholarly journals Anti-Diabetic and Antiresorptive Pharmacotherapies for Prevention and Treatment of Type 2 Diabetes-Induced Bone Disease: Protocol for a Two-Part Systematic Review and Network Meta-Analysis

2019 ◽  
Author(s):  
Jiawen Deng ◽  
Umaima Abbas ◽  
Oswin Chang ◽  
Sayan Dhivagaran ◽  
Stephanie Sanger ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
At Risk ◽  
Bone Disease ◽  
Bone Health ◽  
Risk Of Bias ◽  
Randomized Controlled ◽  
Meta Analyses

ABSTRACTIntroductionPatients with type 2 diabetes mellitus (T2DM) are at risk for a variety of severe debilitating effects. One of the most serious complications experienced by T2DM patients are skeletal diseases caused by changes in the bone microenvironment. As a result, T2DM patients are at risk for higher prevalence of fragility fractures.There are a variety of treatments available for counteracting this effect. Some anti-diabetic medications, such as metformin, have been shown to have a positive effect on bone health without the addition of additional drugs into patients’ treatment plans. Chinese randomized controlled trial (RCT) studies have also proposed antiresorptive pharmacotherapies as a viable alternative treatment strategy. Previous network meta-analyses (NMAs) and meta-analyses regarding this topic did not include all available RCT trials, or only performed pairwise comparisons. We present a protocol for a two-part NMA that incorporates all available RCT data to provide the most comprehensive ranking of anti-diabetics (Part I) and antiresorptive (Part II) pharmacotherapies in terms of their ability to decrease fracture incidences, increase bone mineral density (BMD), improve indications of bone turnover markers (BTMs), and decrease pain in adult T2DM patients.Methods and AnalysisWe will search MEDLINE, EMBASE, PubMed, Web of Science, CINAHL, CENTRAL and Chinese literature sources (CNKI, CQVIP, Wanfang Data, Wanfang Med Online) for randomized controlled trials (RCTs) which fit our criteria. We will include adult T2DM patients who have taken anti-diabetics (Part I) or antiresorptive (Part II) therapies with relevant outcome measures in our study.We will perform title/abstract and full-text screening as well as data extraction in duplicate. Risk of bias (RoB) will be evaluated in duplicate for each study, and the quality of evidence will be examined using CINeMA in accordance to the GRADE framework. We will use R and gemtc to perform the NMA. We will report changes in BMD, BTM and pain scores in either weighted or standardized mean difference, and we will report fracture incidences as odds ratios. We will use the surface under the cumulative ranking curve (SUCRA) scores to provide numerical estimates of the rankings of interventions.Ethics and DisseminationThe study will not require ethics approval. The findings of the two-part NMA will be disseminated in peer-reviewed journals and presented at conferences. We aim to produce the most comprehensive quantitative analysis regarding the management of T2DM bone disease. Our analysis should be able to provide physicians and patients with up-to-date recommendations for anti-diabetic medications and antiresorptive pharmacotherapies for maintaining bone health in T2DM patients.Systematic Review RegistrationInternational Prospective Register for Systematic Reviews (PROSPERO) — CRD42019139320ARTICLE SUMMARYStrengths and limitations of this studyLiterature search in Chinese databases will yield new RCT evidence regarding the efficacy of anti-diabetics in treating T2DM bone diseaseUsing network meta-analytical techniques to analyze the relative efficacy of antiresorptive therapies will allow us to include new treatment arms, such as zoledronic acid and risedronate.Only RCTs will be included and the quality of trials and networks will be evaluated using Risk of Bias, GRADE and comparison-adjusted funnel plots.Chinese clinicians may not use the same procedures and practices as Western clinicians, therefore the outcomes from Chinese RCTs may not apply to the Western healthcare systems.The study design does not allow the comparison of anti-diabetics with antiresorptive therapies or combinations of the two.

scholarly journals The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Daniel J. Devoe ◽  
Gina Dimitropoulos ◽  
Alida Anderson ◽  
Anees Bahji ◽  
Jordyn Flanagan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Substance Use ◽  
Anorexia Nervosa ◽  
Drug Abuse ◽  
Binge Eating ◽  
Substance Use Disorders ◽  
Meta Analysis ◽  
English Summary ◽  
High Prevalence ◽  
Meta Analyses

Abstract Aim Individuals with anorexia nervosa (AN) often present with substance use and substance use disorders (SUDs). However, the prevalence of substance use and SUDs in AN has not been studied in-depth, especially the differences in the prevalence of SUDs between AN types [e.g., AN-R (restrictive type) and AN-BP (binge-eating/purge type]. Therefore, this systematic review and meta-analysis aimed to assess the prevalence of SUDs and substance use in AN samples. Method Systematic database searches of the peer-reviewed literature were conducted in the following online databases: MEDLINE, PsycINFO, Embase, and CINAHL from inception to January 2021. We restricted review eligibility to peer-reviewed research studies reporting the prevalence for either SUDs or substance use in individuals with AN. Random-effects meta-analyses using Freeman–Tukey double arcsine transformations were performed on eligible studies to estimate pooled proportions and 95% confidence intervals (CIs). Results Fifty-two studies met the inclusion criteria, including 14,695 individuals identified as having AN (mean age: 22.82 years). Random pooled estimates showed that substance use disorders had a 16% prevalence in those with AN (AN-BP = 18% vs. AN-R = 7%). Drug abuse/dependence disorders had a prevalence of 7% in AN (AN-BP = 9% vs. AN-R = 5%). In studies that looked at specific abuse/dependence disorders, there was a 10% prevalence of alcohol abuse/dependence in AN (AN-BP = 15% vs. AN-R = 3%) and a 6% prevalence of cannabis abuse/dependence (AN-BP = 4% vs. AN-R = 0%). In addition, in terms of substance use, there was a 37% prevalence for caffeine use, 29% prevalence for alcohol use, 25% for tobacco use, and 14% for cannabis use in individuals with AN. Conclusion This is the most comprehensive meta-analysis on the comorbid prevalence of SUDs and substance use in persons with AN, with an overall pooled prevalence of 16%. Comorbid SUDs, including drugs, alcohol, and cannabis, were all more common in AN-BP compared to AN-R throughout. Therefore, clinicians should be aware of the high prevalence of SUD comorbidity and substance use in individuals with AN. Finally, clinicians should consider screening for SUDs and integrating treatments that target SUDs in individuals with AN. Plain English Summary Individuals with anorexia nervosa (AN) may also present with substance use or have a substance use disorder (SUDs). Thus, we conducted a systematic review and meta-analysis to determine the prevalence of substance use and substance use disorders in individuals with AN. We examined published studies that reported the prevalence of either substance use or SUDs in individuals with AN. We found that substance use disorders had a 16% prevalence and that drug abuse/dependence disorders had a prevalence of 7% in those with AN. These rates were much higher in individuals with binge-eating/purging type compared to the restrictive AN. However, many specific substance use disorders and substance use types were low in individuals with AN. Nonetheless, clinicians should be aware of the high prevalence of SUD comorbidity and substance use in individuals with AN.

scholarly journals Fertility and Reproduction after Recovery from Anorexia Nervosa: A Systematic Review and Meta-Analysis of Long-Term Follow-Up Studies

Diseases ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 46
Author(s):  
Rayane Chaer ◽  
Nour Nakouzi ◽  
Leila Itani ◽  
Hana Tannir ◽  
Dima Kreidieh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anorexia Nervosa ◽  
Reproductive Health ◽  
Narrative Analysis ◽  
Meta Analysis ◽  
Reproductive Function ◽  
Medical Complication ◽  
Pregnancy And Childbirth ◽  
Meta Analyses

Reproductive health is compromised during anorexia nervosa (AN). However, it is still unclear whether this medical complication is reversible after recovery from AN. The purpose of this paper was to conduct a systematic review of the major reproductive health outcomes in females after recovery from AN. The review was conducted in adherence to preferred reporting items for systematic review and meta-analyses (PRISMA) guidelines. Data were collated using meta-analysis and a narrative approach. Of the 1186 articles retrieved, five studies met the inclusion criteria and were reviewed. These studies monitored weight-restored females who had recovered from AN for a follow-up period of between six and 18 years. Their narrative analysis revealed that appropriate treatment of AN leads to the normalization of reproductive function, especially in terms of fertility, pregnancy, and childbirth rates. The meta-analysis confirmed this finding, where the pooled odds of childbirth rates between the AN group and the general population was not statistically significant (OR = 0.75, 95% CI: 0.43–1.29, p = 0.41). We conclude that if patients undergo appropriate eating-disorder treatment and weight restoration, it appears to be unlikely that reproductive health is affected by AN. However, since this finding is derived from only a few studies, it requires replication and confirmation.

scholarly journals Growth factors in Anorexia Nervosa: protocol for a systematic review and meta-analysis of cross-sectional and longitudinal data

2021 ◽  
Author(s):  
Johanna Louise Keeler ◽  
Rosemarie Keeler-Schaffeler ◽  
Hubertus Himmerich ◽  
Janet Treasure
Keyword(s):  
Systematic Review ◽  
Anorexia Nervosa ◽  
Growth Factors ◽  
Growth Factor ◽  
Meta Analysis ◽  
Health Condition ◽  
Individual Growth ◽  
Cross Sectional ◽  
Metabolic Systems ◽  
Meta Analyses

Introduction Anorexia Nervosa (AN) is a serious mental health condition, which commonly follows a chronic course. Recent evidence suggests SE-AN may be underpinned by an interaction between genetic risk factors, the endocrinological, immune and metabolic systems and deficiencies in neural structures. Previous meta-analyses have identified increases in certain pro-inflammatory cytokines in AN, which may contribute to neuroinflammation. However, there has not yet been an investigation of growth factor concentrations in individuals with AN. We aim to conduct a systematic review and meta-analysis of growth factor concentrations in individuals with AN compared to healthy individuals, and of individuals longitudinally (i.e. after an improvement in weight and/or symptoms). Methods and analysis We will use a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). Studies of any design in populations of AN with outcomes pertaining to serum, plasma or cerebrospinal growth factor concentrations will be located using an electronic database search of PudMed, ISI Web of Science Core Collection and MEDLINE. Two reviewers will independently screen titles, abstracts and full-texts and chart data of eligible studies. Study characteristics will be summarised during data analysis. Reported outcomes will include standardised mean differences between groups (AN vs. healthy controls, AN longitudinally) of individual growth factors.

Psychological and Cognitive Aspects of Borderline Intellectual Functioning

2017 ◽  
Vol 22 (3) ◽  
pp. 159-166 ◽  
Author(s):  
Bastianina Contena ◽  
Stefano Taddei
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Intellectual Functioning ◽  
Clinical Impact ◽  
Review Of The Literature ◽  
Borderline Intellectual Functioning ◽  
General Quality ◽  
Meta Analyses ◽  
Over Time

Abstract. Borderline Intellectual Functioning (BIF) refers to a global IQ ranging from 71 to 84, and it represents a condition of clinical attention for its association with other disorders and its influence on the outcomes of treatments and, in general, quality of life and adaptation. Furthermore, its definition has changed over time causing a relevant clinical impact. For this reason, a systematic review of the literature on this topic can promote an understanding of what has been studied, and can differentiate what is currently attributable to BIF from that which cannot be associated with this kind of intellectual functioning. Using Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) criteria, we have conducted a review of the literature about BIF. The results suggest that this condition is still associated with mental retardation, and only a few studies have focused specifically on this condition.

Sign in / Sign up

Export Citation Format

Share Document